Bordetellae and Haemophilus ducreyi
博氏杆菌和杜克雷嗜血杆菌
基本信息
- 批准号:7734838
- 负责人:
- 金额:$ 3.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcidsAntibodiesBacillus (bacterium)BindingBiological AssayBirdsCarrier ProteinsCharacteristicsChemicalsChildCouplingCross ReactionsDeaminationDevelopmentDoseEnzyme-Linked Immunosorbent AssayGlucosamineGoalsGram-Negative BacteriaHemophilus ducreyiHerd ImmunityHumanHydrolysisImmunityIndividualInfantLicensingLipopolysaccharidesMammalsMeasuresMethodologyMethodsMethylationMusO AntigensPertussisPertussis VaccineProceduresPropertyProteinsRespiratory Tract InfectionsSalineSerologicalSerumStructureTemperatureTimeToxinVaccinesVariantanti-IgGbactericidebaseconceptimmunogenicpathogenpreventsugarvaccine efficacy
项目摘要
Bordetellae:
Bordetellae are Gram-negative bacilli causing respiratory tract infections of mammals and birds. Clinically important are B. pertussis, B. parapertussis and B. bronchiseptica. B. pertussis vaccines have been successful in preventing pertussis in infants and children. Veterinary vaccines against B. bronchiseptica are available, but their efficacy and mode of action are not established. There is no vaccine against B. parapertussis. Based on the concept that immunity to non-capsulated Gram-negative bacteria may be conferred by serum IgG anti-LPS we studied chemical, serological and immunological properties of the O-specific polysaccharides (O-SP) of B. bronchiseptica and B. parapertussis obtained by different degradation procedures. One type of the B. parapertussis and two types of B. bronchiseptica O-SP were recognized based on their non-reducing end saccharide structure; no cross-reaction between the two B. bronchiseptica types was observed. Competitive inhibition assays showed the immunodominance of the non-reducing end of these O-SP. Conjugates of B. bronchiseptica and B. parapertussis O-SP were prepared by using the Kdo residue exposed by mild acid hydrolysis of the LPS or the core glucosamine residue exposed by deamination of the LPS, for binding to an aminooxylated protein. Both coupling methods were carried out at a neutral pH, room temperature, and in a short time. All conjugates, injected into mice as saline solutions, at a fraction of an estimated human dose, induced antibodies to the homologous O-SP. These methodologies can be applied to prepare LPS-based vaccines against other Gram-negative bacteria.
The protection afforded by licensed subunit pertussis vaccines is incomplete on an individual basis, likely due to the lack of direct bactericidal effect of anti toxin antibodies. However herd immunity, that occurs with wide vaccine uasage, provides the almost complete protection. An additinal vaccine component inducing bactericidal antibodies such as anti LPS, could increase vaccine efficacy on an individual basis. To that end B. pertussis and B. bronchiseptica LPS were isolated and analyzed. B. pertusis expresses only the core region saccharide (OS) composed of 12 sugars. B. bronchiseptica, easier cultured and with better yields, expresses LPS with almost identical core structure to that of B. pertussis, though we observed small variations: (1) the methylation of Fuc4NMe, 100% in B. pertussis is only 50% in B. bronchiseptica; (2) Hep is phosphorylated in about 30% in B. bronchiseptica,, while in B. petrussis it is not phosphorylated. B. bronchispetica LPS is mostly further substituted by O-specific chains (O-SP). For this study only a free core fraction, with no O-SP was used. Conjugates of both B. pertussis OS and B. bronchiseptica core were prepared by reacting their reducing-end Kdo moieties with an aminooxy linker bound to BSA. Both conjugates incorporated an average of 10 saccharide chains per BSA molecule, both reacted with anti-B. pertussis and anti-BSA sera with a line of identity and both were immunogenic in mice inducing similar antibody levels, measured by ELISA.
Bordetellae:
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rachel Schneerson其他文献
Rachel Schneerson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rachel Schneerson', 18)}}的其他基金
NMR Verification of Structures of Bacterial Saccharide Precursors for Vaccines
疫苗用细菌糖前体结构的核磁共振验证
- 批准号:
7968700 - 财政年份:
- 资助金额:
$ 3.39万 - 项目类别:
Cross Reacting Polysaccharides (H. influenzae types a and b, and B. pumilus)
交叉反应多糖(a 型和 b 型流感嗜血杆菌,以及短小芽孢杆菌)
- 批准号:
8553872 - 财政年份:
- 资助金额:
$ 3.39万 - 项目类别:
Cross Reacting Polysaccharides (H. influenzae types a and b, and B. pumilus)
交叉反应多糖(a 型和 b 型流感嗜血杆菌,以及短小芽孢杆菌)
- 批准号:
7734726 - 财政年份:
- 资助金额:
$ 3.39万 - 项目类别:
NMR Verification of Structures of Bacterial Saccharide Precursors for Vaccines
疫苗用细菌糖前体结构的核磁共振验证
- 批准号:
8149329 - 财政年份:
- 资助金额:
$ 3.39万 - 项目类别:
Vaccine development for Group B Neisseria meningitidis and Escherichia coli K1
B 组脑膜炎奈瑟菌和大肠杆菌 K1 的疫苗开发
- 批准号:
8553955 - 财政年份:
- 资助金额:
$ 3.39万 - 项目类别:
NMR Analysis of Synthetic Oligosaccharide Fragments of the OSP of E. coli O-148
大肠杆菌 O-148 OSP 合成寡糖片段的 NMR 分析
- 批准号:
7734847 - 财政年份:
- 资助金额:
$ 3.39万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 3.39万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:














{{item.name}}会员




